Sugi Predict

Sugi Predict / Compounds / SCHEMBL2595018

SCHEMBL2595018

SCHEMBL2595018

O=[N+]([O-])c1cccc2c1ccn2C1O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SLC29A1 Q99808 6/20 0.48
▸ SLC28A1 O00337 1/20 0.47
▸ SLC28A2 O43868 1/20 0.47
▸ SLC28A3 Q9HAS3 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ THRB P10828 1/20 0.46
▸ MTOR P42345 1/20 0.46
▸ MDM2 Q00987 1/20 0.46
▸ NCOA1 Q15788 1/20 0.46
▸ NCOA3 Q9Y6Q9 1/20 0.46
▸ MAPT P10636 1/20 0.45
▸ CDA P32320 1/20 0.45
▸ SLC5A1 P13866 1/20 0.43
▸ SLC5A2 P31639 1/20 0.43
▸ ADK P55263 2/20 0.43
▸ ADORA3 P0DMS8 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1375866 1.00 SLC29A1 (0.48) SLC29A1SLC28A1SLC28A2SLC28A3LMNA
SCHEMBL12464623 0.80 SLC29A1 (0.43) SLC29A1LMNA
SCHEMBL9127601 0.80 SLC29A1 (0.43) SLC29A1LMNA
SCHEMBL12464370 0.80 SLC29A1 (0.43) SLC29A1LMNA
SCHEMBL9127598 0.80 SLC29A1 (0.43) SLC29A1LMNA
SCHEMBL18025737 0.80 SLC29A1 (0.43) SLC29A1LMNA
SCHEMBL5556122 0.80 SLC29A1 (0.58) SLC29A1SLC28A3ADORA3
SCHEMBL1405594 0.78 SLC5A2 (0.51) SLC29A1SLC28A1SLC28A2SLC28A3LMNA
SCHEMBL6833720 0.78 ADORA3 (0.39) SLC29A1ADORA3
SCHEMBL17179622 0.76 SLC5A2 (0.55) SLC29A1SLC28A1SLC28A2SLC28A3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018195224-A1 BARCODED TRANSPOSASES TO INCREASE EFFICIENCY OF HIGH-ACCURACY GENETIC SEQUENCING FRED HUTCHINSON CANCER RESEARCH CENTER (US) 2018-10-25 — — WO disclosed
WO-2016161177-A1 COMPOSITIONS AND METHODS FOR TARGET NUCLEIC ACID MOLECULE ENRICHMENT FRED HUTCHINSON CANCER RESEARCH CENTER (US) 2016-10-06 — — WO disclosed
US-20150258130-A1 NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF MARINA BIOTECH, INC. (US) 2015-09-17 — — US disclosed
US-20150259686-A1 NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF MARINA BIOTECH, INC. (US) 2015-09-17 — — US disclosed
US-9074205-B2 Nicked or gapped nucleic acid molecules and uses thereof MARINA BIOTECH, INC. (US) 2015-07-07 — — US disclosed
WO-2013036868-A1 SYNTHESIS AND USES OF NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS MARINA BIOTECH INC. (US) 2013-03-14 — — WO disclosed
EP-2563922-A1 NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS AND USES THEREOF Marina Biotech, Inc. (US) 2013-03-06 — — EP disclosed
US-20130011922-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING GENE EXPRESSION AND USES THEREOF F/K/A MDRNA, INC. (US) 2013-01-10 — — US disclosed
WO-2011139710-A1 NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS AND USES THEREOF MARINA BIOTECH, INC. (US) 2011-11-10 — — WO disclosed
US-20100209487-A1 NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF NASTECH PHARMACEUTICAL COMPANY INC. (US) 2010-08-19 — — US disclosed
WO-2008109500-A2 NUCLEIC ACID COMPOUNDS FOR INHIBITING PRKCA GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 — — WO disclosed
WO-2008109454-A2 NUCLEIC ACID COMPOUNDS FOR INHIBITING FOS GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 — — WO disclosed
WO-2008109370-A2 NUCLEIC ACID COMPOUNDS FOR INHIBITING SRD5A1 GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 — — WO disclosed
WO-2008109468-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING MMP GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 — — WO disclosed
WO-2008109551-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING TACSTD1 GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 — — WO disclosed
WO-2008109449-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING BCL2 GENE EXPRESSION AND USES THEREOF MDRNA INC. (US) 2008-09-12 — — WO disclosed
WO-2008109505-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING CD22 GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 — — WO disclosed
WO-2008109452-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING TIE GENE EXPRESSION AND USES THEREOF NASTECH PHARMACEUTICAL COMPANY INC. (US) 2008-09-12 — — WO disclosed
WO-2008109382-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING PKN3 GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 — — WO disclosed
WO-2008022046-A2 DICER SUBSTRATE RNA PEPTIDE CONJUGATES AND METHODS FOR RNA THERAPEUTICS NASTECH PHARMACEUTICAL COMPANY INC. (US) 2008-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130011922-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING GENE EXPRESSION AND USES THEREOF POLRMT, RNMT, SNRPE SLC29A1 128/4885SLC28A1 189/4885SLC28A2 174/4885
US-20150258130-A1 NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF RNMT, POLRMT, SNRPE SLC29A1 82/4885SLC28A1 149/4885SLC28A2 132/4885
US-20100209487-A1 NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF RNMT, POLRMT, SNRPE SLC29A1 82/4885SLC28A1 149/4885SLC28A2 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.